Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Non-Small Cell Lung Cancer Patients

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
Lauren L PalazzoChung Yin Kong

Abstract

Despite reports of socioeconomic disparities in rates of genetic testing and targeted therapy treatment for metastatic non-small cell lung cancer (NSCLC), little is known about whether such disparities are changing over time. We performed a retrospective analysis to identify disparities and trends in genetic testing and treatment with erlotinib. Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we identified 9,900 patients with stage IV NSCLC diagnosed in 2007 to 2011 at age 65 or older. We performed logistic regression analyses to identify patient factors associated with odds of receiving a genetic test and erlotinib treatment, and to assess trends in these differences with respect to diagnosis year. Patients were more likely to receive genetic testing if they were under age 75 at diagnosis [odds ratio (OR), 1.55] independent of comorbidity level, and this age-based gap showed a decrease over time (OR, 0.93). For untested patients, erlotinib treatment was associated with race (OR, 0.58, black vs. white; OR, 2.45, Asian vs. white), and was more likely among female patients (OR, 1.45); for tested patients, erlotinib treatment was less likely among low-income patients (OR, 0.32). Most of these associ...Continue Reading

References

Jun 1, 1992·Journal of Clinical Epidemiology·R A DeyoM A Ciol
Jun 1, 1996·Thorax·J S BrownA G Davison
Jan 9, 2001·Journal of Clinical Epidemiology·C N KlabundeJ L Warren
Mar 3, 2005·Journal of the National Cancer Institute·Hisayuki ShigematsuAdi F Gazdar
Jul 13, 2005·Archives of Internal Medicine·Cary P GrossHarlan M Krumholz
Sep 7, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L M WoodsM P Coleman
Aug 21, 2009·The New England Journal of Medicine·Rafael RosellUNKNOWN Spanish Lung Cancer Group
Dec 22, 2009·The Milbank Quarterly·Ruth R FadenJonathon P Leider
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L CrinòUNKNOWN ESMO Guidelines Working Group
Dec 8, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey R OxnardVincent A Miller
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sunny WangLouise C Walter
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tianhong LiDavid R Gandara
Mar 2, 2013·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Julie A LynchChristopher S Lathan
Feb 5, 2014·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Asal Mohamadi JohnsonA Rana Bayakly
Jan 13, 2015·Cancer Treatment Reviews·Martine T E PutsShabbir M Alibhai
Jan 15, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Particip
Apr 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine Reeder-HayesStacie B Dusetzina
Apr 28, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hui YuFred R Hirsch
Dec 19, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Melisa L WongBenjamin D Kozower
Apr 14, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerMiranda Hughes
May 5, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ya-Chen Tina ShihFabrice Smieliauskas
May 19, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Gregory L Riely
Nov 21, 2017·The New England Journal of Medicine·Jean-Charles SoriaUNKNOWN FLAURA Investigators
Jan 10, 2018·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 21, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J W GoldmanN Rosenfeld

❮ Previous
Next ❯

Citations

May 12, 2021·JCO Oncology Practice·Jacob N SteinSamuel Cykert
Nov 11, 2021·American Journal of Clinical Oncology·Salman R PunekarDaniel J Becker
Jan 27, 2022·Current Oncology Reports·Sharon HarrisonCamille Ragin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.